Indivior PLC
LSE:INDV
Indivior PLC
Revenue
Indivior PLC
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Indivior PLC
LSE:INDV
|
Revenue
$2.1B
|
CAGR 3-Years
36%
|
CAGR 5-Years
24%
|
CAGR 10-Years
7%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Revenue
£31.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Revenue
$54.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
7%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Revenue
$42.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Revenue
$3.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Revenue
£178.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
Indivior PLC
Glance View
Indivior PLC, a pivotal player in the pharmaceutical landscape, traces its roots back to a dedicated focus on addiction treatment. With an origin steeped in addressing opioid dependency, the company carved out a significant niche by developing and marketing medication-assisted treatments. At the heart of Indivior's success is its flagship product, Suboxone, which combines buprenorphine and naloxone to manage opioid addiction. This formulation, integral in combating withdrawal symptoms and reducing the allure of opioids, positioned Indivior as an innovator in an era when the opioid crisis commanded urgent attention. The company's revenue model leverages the growing need for comprehensive drug dependence solutions, primarily driven by its robust portfolio of treatment options. By relentlessly advocating for effective healthcare policies and ensuring substantial product availability, Indivior maintains its competitive edge. The company's strategy is not just confined to novel drug development, but also focuses on expanding treatment access globally, aligning profitability with public health imperatives. This dual commitment to innovation and societal impact ensures that Indivior remains a significant force in the healthcare sector, adeptly navigating the complexities of addiction treatment while generating sustainable financial growth.
See Also
What is Indivior PLC's Revenue?
Revenue
2.1B
USD
Based on the financial report for Mar 31, 2025, Indivior PLC's Revenue amounts to 2.1B USD.
What is Indivior PLC's Revenue growth rate?
Revenue CAGR 10Y
7%
Over the last year, the Revenue growth was 83%. The average annual Revenue growth rates for Indivior PLC have been 36% over the past three years , 24% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet